Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II

Circulation. 2022 Oct 18;146(16):1259-1261. doi: 10.1161/CIRCULATIONAHA.122.057364. Epub 2022 Oct 17.
No abstract available

Keywords: CaMKII; SGLT2 inhibitors; heart failure.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Benzhydryl Compounds / pharmacology
  • Benzhydryl Compounds / therapeutic use
  • Calcium / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism
  • Calmodulin* / metabolism
  • Glucosides / pharmacology
  • Glucosides / therapeutic use
  • Humans
  • Myocytes, Cardiac / metabolism
  • Phosphorylation
  • Sodium* / metabolism

Substances

  • Benzhydryl Compounds
  • Calmodulin
  • Glucosides
  • Sodium
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • empagliflozin
  • Calcium